Revenues for the quarter dropped about 55 percent compared to revenues for the same quarter in 2014.
In addition to offering NIPTs, Natera is eyeing the cancer diagnostics space.
The IPO could bring in $51.4 million in net proceeds for the molecular diagnostics firm.
The microbial genetics analysis firm went public today offering 2.85 million units for $17.1 million in gross proceeds.
The firm expects to receive net proceeds of up to $51.4 million at a price range of $13 to $15 per share for its IPO.
The company issued more than 8.6 million shares at €11.50 per share in its IPO. Its shares list on Euronext Brussels under ticker symbol "BCART."
The microbial genetics analysis firm said in an SEC document that it plans to offer between 2.5 million units of stock and warrants at between $5.50 and $6.50 per unit.
The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
In an SEC document, the company said that current terms were not attractive enough for it to continue with a public offering.
The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.
According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.
New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.
In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.